You are here: vision-research.eu » News

News

Clinical trial suggests pegcetacoplan may slow onset of age-related macular degeneration

An international team of researchers has found via clinical trial that the drug pegcetacoplan may slow the onset of age-related macular degeneration in some people.

Algorithm identifies early vascular disease using photos of the eye

Researchers at the University and the University Hospital of Bonn have developed a method that could be used to diagnose atherosclerosis. Using self-learning software, they were able to identify vascular changes in patients with peripheral arterial disease (PAD), often at an early stage.

Glaucoma: Seeing the light at the end of the tunne

Reduced blood flow and impaired neurovascular coupling are well-known features of glaucoma, the main cause of non-curable blindness affecting 80 million people worldwide in 2020. The mechanisms underlying these abnormalities are now unveiled, thanks to new research by a team led by Adriana Di Polo, professor of neuroscience and ophthalmology at Université de Montréal.

Implanted chip, natural eyesight coordinate vision in study of macular degeneration

Two years ago, a Stanford researcher and his team showed that with a thin, pixelated chip and specially designed glasses, they could restore limited vision in the center of the visual field of patients suffering from macular degeneration. In a recent, follow-up study, the researchers found that this prosthetic vision naturally integrated with the patients' peripheral vision, which was unaffected by the disease.

Open-access publishing fees deter researchers in the global south

Authors in low-income countries rarely published free-to-read papers, even when they qualified for publication-fee waivers.

Ocuphire Pharma completes enrollment in MIRA-3 Pivotal Phase 3 clinical trial for Nyxol in RM

The company completed enrollment ahead of schedule in a second Phase 3 FDA registration trial for Nyxol in RM with top-line results expected by the end of the first quarter.

Choroidal thickness reduced for individuals with migraine

Mahdi Gouravani, from the Tehran University of Medical Sciences in Iran, and colleagues conducted a meta-analysis to examine choroidal thickness measurements for individuals with migraine and healthy individuals.

Trials show promise for intravitreal faricimab in retinal disease

Faricimab is noninferior to aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema, according to two studies published in The Lancet.

Aqueous biomarkers may help predict treatment response in neovascular age-related macular degeneration

Aqueous biomarkers could help identify patients with neovascular age-related macular degeneration (nvAMD) who may not require, or who may not benefit from, long-term antivascular endothelial growth factor (VEGF) therapy.

eSight, Be My Eyes announce sweepstakes winner

The Toronto-based medical eyewear company partnered with the visual assistance community to help empower an Oregon college student with enhanced vision.

Researchers discover cause, develop pharmacological treatment for reducing retinitis pigmentosa vision loss

Researchers from the University of California, Irvine have discovered that the absence of Adiponectin receptor 1 protein (AdipoR1), one of the principal enzymes regulating ceramide homeostasis in the retina, leads to an accumulation of ceramides in the retina, resulting in progressive photoreceptor cell death and ultimately vision loss.

Improved retinal transplant technique ready for clinical trials

Researchers led by Michiko Mandai at the RIKEN Center for Biosystems Dynamics Research (BDR) in Japan have used a genetic modification to improve human-derived retina transplants grown in the lab.

What faricimab for DME means for safe, durable treatment over the long term

The results of the YOSEMITE and RHINE phase 3 trials that evaluated the efficacy of faricimab (Vabysmo, Genentech) for treating center-involved diabetic macular edema (DME) compared with aflibercept (Eylea, Regeneron Pharmaceuticals) found that after 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

European Commission appoints the new members of the European Group on Ethics in Science and New Technologies

The European Commission appointed the 15 new members of the new European Group on Ethics in Science and New Technologies (EGE).

New data on drug metabolism and distribution in the eye

Severe visual illnesses are increasing in our society, and effective treatments are missing for diseases as age-related macular degeneration, diabetic retinopathy, and glaucoma. Both industry and academia are highly interested to advance ocular drug discovery and development. Ocular pharmacokinetics is a key science in this process, and knowledge of drug metabolism and distribution in the eye is required.